Kmira Z, Nesrine BS, Houneida Z, Wafa BF, Aida S, Yosra BY, Monia Z, Sriha B, Abderrahim K. Severe hemorrhagic colitis in a patient with chronic myeloid leukemia in the blastic phase after dasatinib use. World J Gastrointest Pathophysiol 2013; 4(3): 59-62 [PMID: 23946889 DOI: 10.4291/wjgp.v4.i3.59]
Corresponding Author of This Article
Dr. Zahra Kmira, Department of Clinical Hematology, University Hospital Farhat Hached, Avenue Ibn Eljazzar, Sousse 4000, Tunisia. kmira_zahra@yahoo.fr
Research Domain of This Article
Hematology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Pathophysiol. Aug 15, 2013; 4(3): 59-62 Published online Aug 15, 2013. doi: 10.4291/wjgp.v4.i3.59
Severe hemorrhagic colitis in a patient with chronic myeloid leukemia in the blastic phase after dasatinib use
Zahra Kmira, Ben Sayed Nesrine, Zaghouani Houneida, Ben Fredj Wafa, Slama Aida, Ben Youssef Yosra, Zaier Monia, Badreddine Sriha, Khelif Abderrahim
Zahra Kmira, Ben Sayed Nesrine, Ben Fredj Wafa, Ben Youssef Yosra, Zaier Monia, Khelif Abderrahim, Department of Clinical Hematology, University Hospital Farhat Hached, Sousse 4000, Tunisia
Zaghouani Houneida, Department of Radiology, University Hospital Farhat Hached, Sousse 4000, Tunisia
Slama Aida, Department of Gastroenterology, University Hospital Sahloul, Sousse 4000, Tunisia
Badreddine Sriha, Department of Anatomopathology, University Hospital Farhat Hached, Sousse 4000, Tunisia
Author contributions: All authors contributed to this work.
Correspondence to: Dr. Zahra Kmira, Department of Clinical Hematology, University Hospital Farhat Hached, Avenue Ibn Eljazzar, Sousse 4000, Tunisia. kmira_zahra@yahoo.fr
Telephone: +216-21-135521
Received: June 23, 2013 Revised: July 17, 2013 Accepted: August 4, 2013 Published online: August 15, 2013
Core Tip
Core tip: Dasatinib is a second-line tyrosine kinase inhibitor used in imatinib resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute leukemia patients. Dasatinib, which binds to the active and inactive conformation of the BCR-ABL oncoprotein, demonstrates greater potency than imatinib for wild-type and mutant BCR-ABL cases, with the exception of the T315I mutation. The most frequent adverse effects include myelosuppression, diarrhea, nausea and peripheral edema. Severe dasatinib-relatedacute colitis without thrombocytopenia, coagulation abnormalities or colonic ulcers has rarely been reported. Here, we report the case of an adult patient with Philadelphia chromosome positive CML in the blastic phase who developed acute colitis after dasatinib use.
